Surgery with or without Carboplatin in Treating Patients with Recurrent Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Status: Active

Description

This randomized phase II trial studies how well surgery with or without carboplatin works in treating patients with ovarian, primary peritoneal cavity, or fallopian tube cancer that has come back. Drugs used in chemotherapy, such as carboplatin, work in different ways to the stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen after surgery may kill more tumor cells.

Eligibility Criteria

Inclusion Criteria

  • INCLUSION CRITERIA FOR ELIGIBILITY PRIOR TO SURGERY:
  • Patients with histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma that has recurred > 6 months since platinum-based chemotherapy (first recurrence) and who are scheduled for secondary surgical evaluation/cytoreduction
  • Histologic epithelial cell types include serous, endometrioid, clear cell, or undifferentiated carcinomas, transitional cell carcinoma, mixed epithelial carcinoma, malignant Brenner's tumor, or adenocarcinoma not otherwise specified (NOS)
  • Karnofsky performance status (KPS) of >= 70%
  • Disease-free interval =< 30 months
  • No prior chemotherapy in the recurrent setting; prior hormonal therapy is permitted; concomitant anti-neoplastic anti-hormonal therapy (including tamoxifen, aromatase inhibitors etc.) is not allowed for patients participating in study treatment; low-dose (physiologic) estrogen hormone-replacement therapy (HRT) may be given
  • Patients receiving maintenance biologic therapy are eligible, provided their recurrence is documented more than 6 months from completion of primary cytotoxic chemotherapy (includes maintenance chemotherapy) and a minimum of 3 weeks has elapsed since their last infusion of biologic therapy at the start of protocol intervention, day 1
  • Patients must be, after evaluation by the investigator, appropriate candidates for the administration of 5 to 6 cycles of standard platinum-based combination chemotherapy (carboplatin and paclitaxel, carboplatin and liposomal doxorubicin, or carboplatin and gemcitabine) following CRS with or without HIPEC
  • Hemoglobin >= 8.5 g/dL
  • Absolute neutrophil count (ANC) >= 1,000/mm^3
  • Platelets >= 100,000/mm^3
  • Creatinine =< 1.5 mg/dl
  • Bilirubin =< 1.5 times upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) =< 3 times the ULN
  • Aspartate aminotransferase (AST) =< 3 times the ULN
  • Peripheral neuropathy =< Common Terminology Criteria for Adverse Events (CTCAE) grade 2
  • Prothrombin time (PT) with an international normalized ratio (INR) =< 1.5 and a partial thromboplastin time (PTT) of =< 1.5 times the ULN; for patients on full-dose oral anti-coagulation (such as warfarin or rivaroxaban), in-range INR (usually between 2 and 3) and a PTT < 1.2 times the ULN
  • Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to CRS and must be practicing an effective form of contraception during the study period
  • INCLUSION CRITERIA FOR ELIGIBILITY POST-SURGERY:
  • Patients will be consented prior to the surgical evaluation/cytoreductive surgery; patients must have less than or equal to 0.5 cm residual disease at the completion of the secondary surgery to be eligible for the study

Exclusion Criteria

  • EXCLUSION CRITERIA FOR ELIGIBILITY PRIOR TO SURGERY:
  • Tumors of low malignant potential (borderline carcinomas)
  • Subjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
  • Patients with a history of primary endometrial cancer are excluded unless the following conditions are met: * Stage not greater than IA * Not a poorly differentiated subtype (including papillary serous, clear cell or other International Federation of Gynecology and Obstetrics [FIGO] grade 3 lesions)
  • With the exception of non-melanoma skin cancer and other specific malignancies as noted above, subjects with other invasive malignancies, who had any evidence of the other cancer present within the last 1 year or whose previous cancer treatment contraindicates this protocol therapy, are excluded
  • Subjects with known active acute hepatitis
  • Subjects with active infection that requires parenteral antibiotics
  • Active coronary artery disease (defined as unstable angina or a positive cardiac stress test)
  • Patients with a history of coronary artery disease may be included if they have had a normal stress test within 30 days of enrollment
  • Uncontrolled hypertension defined as > 140/90 and not cleared for surgery at the time of consent
  • New York Heart Association (NYHA) class II or higher congestive heart failure
  • History of cerebrovascular disease
  • Immune deficiency: clinically significant primary or acquired immune deficiency (i.e. acquired immunodeficiency syndrome [AIDS] or on immunosuppressive medication after organ transplant)
  • Patients with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study
  • Patients with known carboplatin or cisplatin allergy
  • Life expectancy < 12 weeks
  • EXCLUSION CRITERIA FOR ELIGIBILITY POST-SURGERY:
  • Evidence of extensive intraperitoneal adhesions at the time of surgery, as determined by the operating surgeon which prohibits intraperitoneal therapy

Locations & Contacts

Connecticut

New Britain
Hartford HealthCare Cancer Institute
Status: Active
Contact: Amy Kirkpatrick Brown
Phone: 860-545-5363
Email: abrown02@harthosp.org

Florida

Miami
Advanced Medical Specialties-Miami Cancer Institute
Status: Active
Contact: John Paul Diaz
Phone: 305-666-1811

Illinois

Chicago
University of Chicago Comprehensive Cancer Center
Status: Active
Contact: John William Moroney
Phone: 773-702-8222

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: Active
Contact: Oliver Zivanovic
Phone: 212-639-7033
Middletown
Memorial Sloan Kettering Monmouth
Status: Active
Contact: Oliver Zivanovic
Phone: 212-639-7033
Montvale
Memorial Sloan Kettering Bergen
Status: Active
Contact: Oliver Zivanovic
Phone: 212-639-7033

New York

Commack
Memorial Sloan Kettering Commack
Status: Active
Contact: Oliver Zivanovic
Phone: 212-639-7033
New York
Memorial Sloan Kettering Cancer Center
Status: Active
Contact: Oliver Zivanovic
Phone: 212-639-7033
Uniondale
Memorial Sloan Kettering Nassau
Status: Active
Contact: Oliver Zivanovic
Phone: 212-639-7033
West Harrison
Memorial Sloan Kettering Westchester
Status: Active
Contact: Oliver Zivanovic
Phone: 212-639-7033

Virginia

Falls Church
Inova Fairfax Hospital
Status: Approved
Contact: George Larry Maxwell
Phone: 703-776-6040

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To determine the proportion of patients who are without evidence of disease progression at 24 months after cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC).

SECONDARY OBJECTIVES:

I. To determine the toxicity and postoperative complications rate in both arms during the 4 week postoperative period.

II. To determine the completion rate of four cycles of intravenous standard platinum-based chemotherapy in both arms.

III. To assess the pharmacokinetics in a subset of patients randomized to receive HIPEC in the operating room (OR).

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients undergo standard CRS and receive hyperthermic carboplatin intraperitoneally (IP) over 90 minutes. Within 4-6 weeks after surgery, patients receive standard intravenous (IV) platinum chemotherapy at the discretion of the physician and patient. Treatment repeats every 3-4 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients undergo standard CRS. Within 4-6 weeks after surgery, patients receive standard IV platinum-based chemotherapy at the discretion of the physician and patient. Treatment repeats every 3-4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 6, 12, 18, and 24 months.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Oliver Zivanovic

Trial IDs

Primary ID 12-275
Secondary IDs NCI-2013-00405
Clinicaltrials.gov ID NCT01767675